TubeRank
LCIDBullmiss
Lucid CityLucid City

Target Price

$12.34

the next big thing for Lucid, which could be tested tomorrow, is going to be that 50-day moving average sitting at 1234.@ 7:23 · open at this moment on YouTube ↗

Thesis at the time

Bullish

Lucid is up 3.53% on broader market optimism plus PIF reaffirmation news via Canaccord analyst Andre Shepard, who confirmed PIF remains committed to Lucid long-term. A new 2x short ETF on LCID launched suspiciously during the rally, which the speaker sees as manipulation but notes the cost to borrow (245%) makes it impractical for retail. Two consecutive days above the 10-day moving average set up a potential test of the 50-day MA at $12.34. The speaker identifies $9.50 as the confirmed floor having called it weeks earlier.

Key arguments

  • PIF confirmed as committed long-term via Canaccord (Andre Shepard) analyst note
  • Lucid up 3.53% — two consecutive days above 10-day MA signals confirmed trend
  • 50-day moving average at $12.34 is the next key technical target
  • New 2x short ETF on LCID launched during rally — timing seen as suspicious
  • Speaker previously called $9.50 as floor — confirmed as accurate in hindsight

Counter-arguments acknowledged

  • New 2x short ETF adds a new tool for bears to suppress the stock
  • Algorithmic trading still the primary volume source — genuine buying is secondary

The call

Date said
Jan 22, 2026
Deadline
Jan 23, 2026
Price at prediction
$11.47
Confidence
medium
Specificity
specific

How it resolved

Status
miss
Resolution price
$11.06
Return
-3.6%
Notes
Deadline passed. Only 0% progress toward target $12.34. Price: $11.06.
Why this resolved this way(resolution audit)
Reference price
$11.47 (anchored at quote date)
Target used
$12.34
Deadline source
Explicit (extracted from quote)
Effective: Jan 23, 2026
Age at resolution
0.0 months(from publish date)
Resolution snapshot
$11.06 on Jan 23, 2026

Rule that fired

Deadline passed. Only 0% progress toward target $12.34. Price: $11.06.

Full rules: docs/resolution-spec.md.